Genecast Pan-Cancer Focus is our proprietary multi-gene detection reagent kit used in NGS-based test for NSCLC and CRC. It utilizes amplicon-based targeted DNA and RNA NGS to determine mutations in 41 genes and provide therapy selection for the patients.

Genecast Pan-Cancer Focus covers 41 NCCN-recommended Tier 1 genes and MSI, enabling targeted mutation detection through dual DNA and RNA analysis. The panel identifies key alterations, including SNVs, indels, CNVs, MSI at DNA level, and gene fusions at RNA level, which are critical for guiding treatment decisions. With a streamlined multiplexed amplicon library construction, it delivers rapid results within 24 hours, facilitating timely clinical decisions. Requiring only 10 ng of DNA and 50 ng of RNA, it is compatible with biopsy samples, ensuring high sensitivity and efficiency even with minimal input material.

Genecast Pan-Cancer Focus supports a wide range of therapy regimens based on rigorous clinical evidence across multiple cancer types, including NSCLC, CRC, GC, GIST, melanoma, and beyond. It detects actionable genetic variants such as base substitutions, fusions, indels, CNVs, in key genes like EGFR, ALK, ROS1, MET, BRAF and KRAS. This enables personalized treatment decisions with targeted therapies such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. By aligning with NCCN guidelines, Genecast Pan-Cancer Focus empowers clinicians to provide precision care tailored to each patient’s genetic profile.

We obtained CE marking for Genecast Pan-Cancer Focus for NSCLC and CRC in March 2022.